|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.378 USD | -3.20% |
|
-6.67% | -48.93% |
| Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
| Mar. 26 | US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings | MT |
NeuBase Therapeutics, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was USD 33.78 million compared to USD 25.41 million a year ago. Basic loss per share from continuing operations was USD 20.8 compared to USD 18.6 a year ago.
Diluted loss per share from continuing operations was USD 20.8 compared to USD 18.6 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -48.93% | 1.42M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
NEUBASE THERAPEUTICS, INC. 